Industry: Drug Manufacturing, Pharmaceuticals, Biotechnology
Vasogen is a leader in the research and commercial development of immune modulation therapies targeting the chronic inflammation underlying cardiovascular disorders. Vasogen’s lead product, Celacade (immune modulation therapy) is currently in phase III clinical trials for the treatment of chronic heart failure and peripheral arterial disease. Celacade is designed to target chronic inflammation by activating the immune system’s physiological anti-inflammatory response to apoptotic cells. Celacade up-regulates the expression of cell surface molecules that interact with specific receptors on antigen presenting cells (APCs) to modulate the production of cytokines – potent chemical messengers that initiate and control ( www.vasogen.com )
Vasogen Inc.
2155 Dunwin Drive Unit #10
Mississauga, Ontario L5L 4M1
Canada
Tel: (905) 569-2265
Fax: (905) 569-9231